Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab DDI Study in UC and CD
NCT02760615Phase 4Withdrawn
- Sponsor
- Takeda
- Start
- Nov 2016
- Primary completion
- Aug 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of vedolizumab in ulcerative colitis (UC), Crohn's disease, sponsored by Takeda. Planned start Nov 2016; status: withdrawn.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02760615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760615.